NDAINHALATIONGAS
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
NITROUS OXIDE, USP (nitrous oxide) by Advanced Solutions Life Sciences. Approved for anesthesia, sedation, pain and 2 more indications. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nitrous oxide (N2O) is a colorless, odorless inhalation gas approved for anesthesia, sedation, and analgesia across multiple clinical settings including dental, surgical, and pain management procedures. The drug works as a CNS depressant, though its precise mechanism of action remains incompletely characterized. It is indicated for anesthesia, sedation, pain relief, dental anxiety reduction, and as an adjunctive agent in glaucoma management.
Peak
Nitrous oxide is at peak lifecycle stage with moderate competitive pressure (30), indicating stable market presence and established team structure but limited growth acceleration opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (5)
Worked on NITROUS OXIDE, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.